MGX
$1.23
+$0.00 (0.00%)+0.00%
After HoursLoading chart...
IndexN/A
Market Cap0.05B
Enterprise Value0.06B
Income$-0.03B
Sales$0.00B
EmployeesN/A
P/E-0.53
P/S2.39
P/B0.38
P/C-0.67
EV/EBITDA-0.72
EV/SalesN/A
EPS (ttm)-2.30
EarningsN/A
Gross Margin78.91%
Oper. Margin-380.85%
Profit Margin-348.54%
Volume0.08M
Shs Outstand0.04B
Change0.00%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Revenue | $52.30M | $44.76M | $17.20M | $243.00K |
| Cost of Revenue | $0.00 | $94.40M | $1.73M | $387.00K |
| Gross Profit | $52.30M | $-49.65M | $15.47M | $-144.00K |
| Gross Margin | 100.00% | -110.93% | 89.92% | -59.26% |
| Operating Expenses | $141.20M | $28.84M | $60.11M | $23.80M |
| Operating Income | $-88.90M | $-78.49M | $-44.64M | $-23.95M |
| Operating Margin | -170.00% | -175.38% | -259.53% | -9854.73% |
| Net Income | $-78.06M | $-68.25M | $-43.59M | $-21.44M |
| Net Margin | -149.26% | -152.50% | -253.45% | -8823.87% |
| EPS (Basic) | $-2.09 | $-1.82 | $-1.16 | $-3.62 |
| EBITDA | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A |
| Total Assets | $324.60M | $364.84M | $414.49M | $141.99M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A |
| Total Liabilities | $89.74M | $149.67M | $488.91M | $174.54M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $234.86M | $215.17M | $-74.43M | $-32.54M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A |
| Total Equity | $234.86M | $215.17M | $-74.43M | $-32.54M |
| Total Liabilities & Stockholders Equity | $324.60M | $364.84M | $414.49M | $141.99M |
| Book Value Per Share | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Net Income | $-78.06M | $-68.25M | $-43.59M | $-21.44M |
| Depreciation | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $-109.07M | $-91.41M | $29.72M | $24.26M |
| Capital Expenditures | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Hemophilia Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsightGlobeNewswire Inc. Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing EfficiencyGlobeNewswire Inc. Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025GlobeNewswire Inc. Metagenomi to Present at Upcoming Scientific MeetingsGlobeNewswire Inc. Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial OfficerGlobeNewswire Inc. Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual MeetingGlobeNewswire Inc. היום הוא המועד לתביעה נגד MGX: רוזן, פירמת עורכי דין מהשורה הראשונה, מעודדת את משקיעי Metagenomi, Inc לקבל ייעוץ לפני התאריך החשוב היום 25 בנובמבר בתביעה ייצוגית בניירות ערך – MGXGlobeNewswire Inc. תאריך היעד לתביעה נגד MGX ביום שני: רוזן, משרד עורכי דין מהשורה הראשונה, מעודד את המשקיעים ב- Metagenomi, Inc לקבל ייעוץ לפני תאריך יעד חשוב של 25 בנובמבר בתביעה ייצוגית בניירות ערך – MGXGlobeNewswire Inc.
Show 12 more stories
DEADLINE NEXT WEEK: Berger Montague Advises Metagenomi (NASDAQ: MGX) Investors to Contact the Firm Before November 25, 2024GlobeNewswire Inc. DEADLINE ALERT for BMBL, MGX, POWW, FNA: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of ShareholdersGlobeNewswire Inc. SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MetagenomiGlobeNewswire Inc. MGX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Metagenomi, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitGlobeNewswire Inc. METAGENOMI ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Metagenomi, Inc. and Encourages Investors to Contact the FirmGlobeNewswire Inc. MGX DEADLINE NOTICE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Metagenomi, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – MGXGlobeNewswire Inc. DEADLINE ALERT for BMBL, MGX, POWW, FNA: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of ShareholdersGlobeNewswire Inc. DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MetagenomiGlobeNewswire Inc. DEADLINE ALERT for MGX, POWW, and FNA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of ShareholdersGlobeNewswire Inc. METAGENOMI, INC. (NASDAQ: MGX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Metagenomi, Inc. Investors of Upcoming DeadlineGlobeNewswire Inc. MGX DEADLINE NOTICE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Metagenomi, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MGXGlobeNewswire Inc. DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors of Metagenomi to Contact Us to Have Their Losses Evaluated TodayGlobeNewswire Inc.
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
Discover more
You may be interested in